Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Blood (2019) 134 (Supplement_1): 4158.

https://doi.org/10.1182/blood-2019-129751

Published: 2019

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Blood (2016) 128 (22): 5987.

https://doi.org/10.1182/blood.V128.22.5987.5987

Published: 2016

Journal Articles

Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience

Daniele Avenoso, Anne Bradshaw, Andrew Innes, Josu de la Fuente, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 5741.

https://doi.org/10.1182/blood.V128.22.5741.5741

Published: 2016

Journal Articles

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Mary Alikian, MSc, PhD, Alexandra S. Whale, Simon Cowen, Kim Piechocki, Michael John Griffiths, BSc, Alistair G Reid, BSc, PhD, Susanna Akiki, Jane F. Apperley, MD, Jim F. Huggett, Letizia Foroni

Blood (2016) 128 (22): 3104.

https://doi.org/10.1182/blood.V128.22.3104.3104

Published: 2016

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation

Blood (2016) 128 (22): 3374.

https://doi.org/10.1182/blood.V128.22.3374.3374

Published: 2016

Journal Articles

An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party

Eolia Brissot, MD PhD, Myriam Labopin, MD, Domenico Russo, MD, Sonja Martin, MD, Christoph Schmid, MD, Bertram Glass, MD, Ron Ram, Zubeyde Nur Ozkurt, Jakob Passweg, Joan Hendrik Veelken, MD PhD, Donald Bunjes, Jane F. Apperley, MD, Mohamad Mohty, MD PhD, Sebastian Giebel, Arnon Nagler

Blood (2016) 128 (22): 3497.

https://doi.org/10.1182/blood.V128.22.3497.3497

Published: 2016

Journal Articles

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Jane F. Apperley, MD, Jenny L. Byrne, FRCP FRCPath PhD, Graeme Smith, Simone Claudiani, Andrea Viqueira, Roxanne Ferdinand, Angela M Carter, Georgina Nock, Dragana Milojkovic

Blood (2016) 128 (22): 5435.

https://doi.org/10.1182/blood.V128.22.5435.5435

Published: 2016

Journal Articles

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Julie Beckerson, Richard M Szydlo, Mary Hickson, Catriona E Mactier, Andrew Innes, Ian H Gabriel, Renuka Palanicawandar, Edward J Kanfer, Donald Macdonald, Dragana Milojkovic, Amin Rahemtulla, Aristeidis Chaidos, Anastasios Karadimitris, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 2226.

https://doi.org/10.1182/blood.V128.22.2226.2226

Published: 2016

Journal Articles

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

Oscar M. Pello, Anne Bradshaw, Andrew Innes, Sally-Anne Finn, Emma Bray, Shab Uddin, Eduardo Olavarria, Jane F. Apperley, MD, Jiří Pavlů

Blood (2016) 128 (22): 5726.

https://doi.org/10.1182/blood.V128.22.5726.5726

Published: 2016

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

Simone Claudiani, Nikhita Gupta, BSc, Ji Soo Baik, BSc, Simona Deplano, MDPhD, Renuka Palanicawander, Gareth Gerrard, Alistair G Reid, BSc, PhD, Richard M Szydlo, BSc, PhD, Dragana Milojkovic, Letizia Foroni, Jane F. Apperley, MD

Blood (2015) 126 (23): 2794.

https://doi.org/10.1182/blood.V126.23.2794.2794

Published: 2015

Journal Articles

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Jeeyune Bahk, BSc, Simone Claudiani, MD, Richard M Szydlo, BSc, PhD, Sarmad Toma, BSc, Faisal Abdillah, BSc, Sandra Hing, BSc, Simona Deplano, MDPhD, Dragana Milojkovic, Jane F Apperley, MD, Letizia Foroni, MD PhD

Blood (2015) 126 (23): 2795.

https://doi.org/10.1182/blood.V126.23.2795.2795

Published: 2015

Journal Articles

Mortality and Morbidity in 15-Year Survivors of Stem Cell Transplants for Haematological Malignancy

Jack Stuart, Richard Szydlo, PhD, Jane F. Apperley, MD, Jeannie Todd, PhD, Nina Salooja, DM, FRCP, FRCPath

Blood (2015) 126 (23): 4348.

https://doi.org/10.1182/blood.V126.23.4348.4348

Published: 2015

Journal Articles

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Blood (2015) 126 (23): 868.

https://doi.org/10.1182/blood.V126.23.868.868

Published: 2015

NARROW

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions

Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation

An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party

The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia

Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)

The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)

Mortality and Morbidity in 15-Year Survivors of Stem Cell Transplants for Haematological Malignancy

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only